Mackenzie Financial’s 10x Genomics TXG Stock Holding History

Mackenzie Financial’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-28,251	Closed	-$247K	–	1800
2025 Q1	$247K	Sell	28,251 -25,139	-47%	-$317K	﹤0.01%	1450
2024 Q4	$767K	Buy	53,390 +21,817	+69%	+$344K	﹤0.01%	1016
2024 Q3	$713K	Buy	+31,573	New	+$653K	﹤0.01%	939
2024 Q2	–	Sell	-13,405	Closed	-$503K	–	1629
2024 Q1	$503K	Buy	+13,405	New	+$589K	﹤0.01%	1024
2022 Q2	–	Sell	-4,191	Closed	-$319K	–	1549
2022 Q1	$319K	Sell	4,191 -11,527	-73%	-$1.01M	﹤0.01%	1091
2021 Q4	$2.34M	Sell	15,718 -6,534	-29%	-$1M	﹤0.01%	744
2021 Q3	$3.24M	Buy	22,252 +2,074	+10%	+$356K	﹤0.01%	653
2021 Q2	$3.95M	Buy	20,178 +12,831	+175%	+$2.32M	0.01%	602
2021 Q1	$1.33M	Buy	7,347 +2,703	+58%	+$467K	﹤0.01%	768
2020 Q4	$658K	Buy	+4,644	New	+$674K	﹤0.01%	782

Other funds holding TXG

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mackenzie Financial's TXG Position: Q2 2025 in Review

Mackenzie Financial sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 28,251 shares — an estimated $247K sold.

Mackenzie Financial first reported a position in TXG in Q4 2020 and held it in 10 quarters. The position peaked at $3.95M in Q2 2021. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

Mackenzie Financial reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
Mackenzie Financial sold 28,251 10x Genomics shares in Q2 2025, an estimated $247K.
Mackenzie Financial first reported a position in 10x Genomics in Q4 2020 and held it in 10 quarters.
Mackenzie Financial's 10x Genomics position peaked at $3.95M in Q2 2021.
297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Mackenzie Financial's 13F filing for Q2 2025, filed 13 Aug 2025.